



# NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support

12 Apr 2021 (#10)

*[Click on blue [hyperlink](#) for further information]*

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit [www.grants.nih.gov](http://www.grants.nih.gov) or [www.sun.ac.za/RDSfunding](http://www.sun.ac.za/RDSfunding) (current & archive).

**Confirm your intent to apply ASAP, but not later than 60 days before the submission date.**

Tygerberg Campus: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) • Stellenbosch Campus [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za)

## Important Notices

**[Know How to Answer Just-in-Time Requests](#)**. If your grant application scores near or within the [NIAID Paylines](#) or an NIAID program officer indicates your application may be in the fundable range and requests additional information needed for a potential award, your next step is to submit just-in-time (JIT) information. Much of the requested JIT information is routine, but be aware: Certain codes in your summary statement can indicate an award restriction or bar to award, which can block you from funding until you resolve underlying scientific review concerns about human subjects (HS) involvement, HS inclusion, or animal welfare in your application.

## Notices of Special Interest (NOSI)

**[NOT-OD-21-087](#) Developing and Testing Multilevel Physical Activity Interventions to Improve Health and Well-Being**. The Office of Disease Prevention and participating ICOs are issuing this Notice to highlight our interest in encouraging highly innovative and promising translational research to improve our understanding of how to increase and maintain health-enhancing physical activity using multi-level interventions in a wide range of population groups across the lifespan (e.g., including racial and ethnic minorities, children, older adults, persons with medical/behavioral health conditions, and persons with disabilities). This includes efficacy, effectiveness and dissemination and implementation studies. It also includes support for pilot, exploratory, or developmental work in preparation for full-scale, fully powered efficacy studies, preliminary feasibility studies, as well as expanded feasibility work for a discrete, specified, circumscribed project that is based on well-established theory, existing data and evidence-based interventions. Applicants must select the IC and associated FOA to use for submission of an application in response to this NOSI. The selection must align with the IC requirements listed in order to be considered responsive to that FOA. Investigators planning to submit an application in response to this NOSI are strongly encouraged to contact and discuss their proposed research/aims with Program staff/Scientific Contacts listed on this NOSI well in advance of the application receipt date to better determine appropriateness and interest of the relevant Institute.

**[NOT-OD-21-089](#) Support for existing data repositories to align with FAIR and TRUST principles and evaluate usage, utility, and impact**. The goal of this Notice of Special Interest (NOSI) is to strengthen NIH-funded biomedical data repositories to better enable data discoverability, interoperability, and reuse by aligning with the FAIR and TRUST principles and using metrics to measure their effectiveness. This NOSI provides an opportunity for existing repositories to increase "FAIR"-ness and "TRUST"-worthiness to improve their usage, utility, and impact throughout the data resource lifecycle. To be responsive to this NOSI, applications must: Propose work for a biomedical data repository and include a self-assessment that identifies gaps or deficiencies to be addressed in one or more of the following areas: "FAIR"-ness, "TRUST"-worthiness, and/or metrics.

**[NOT-OD-21-100](#) Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health**. This Notice of Special Interest (NOSI) is being issued by the NIH Adherence Network through the Office of Behavioral and Social Sciences Research (OBSSR) with participation from multiple NIH Institutes, Centers, and Offices. This NOSI calls

for research grant applications that address patient adherence to treatment and prevention regimens to promote health outcomes. Applications may address healthcare regimen initiation, implementation, and/or persistence by patients. Descriptive and intervention research may address adherence determinants at one or more levels of ecologic influence, including the patient, caregiver/family, provider, healthcare system, and community levels. The specific research interests of participating NIH Institutes and Centers are detailed within. This notice applies to due dates on or after May 7, 2021 and subsequent receipt dates through June 8, 2024. Investigators planning to apply in response to this NOSI are strongly encouraged to contact and discuss their proposed research/aims with a relevant Scientific/Research Contact well in advance of the planned submission date.

## Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

## Funding Opportunity Announcements (FOA)

### 1. Mechanism-Focused Research to Promote Adherence to Healthful Behaviors to Prevent Mild Cognitive Impairment (MCI) and Alzheimer's Disease and Related Dementias (AD/ADRD) (Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-21-207](#)

**Type:** R01

**Application Due Date:** September 15, 2021 and January 26, 2022. Apply by 5:00 PM local time of applicant organization

**Funding Opportunity Announcement:** This Funding Opportunity Announcement (FOA) invites R01 applications for ancillary studies that address psychological and interpersonal mechanisms driving adherence to behavior or lifestyle change relevant to the prevention of cognitive decline, Mild Cognitive Impairment (MCI), and Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). Successful applications will seek to identify malleable, mechanistic, psychological, or interpersonal targets that – if modified – will strengthen adherence to, maintenance of, and continued/renewed engagement in behaviors that may promote cognitive health and prevent AD/ADRD.

This FOA will specifically support ancillary studies to ongoing, early- to late-stage clinical intervention trials. Ancillary studies should provide the opportunity to explore novel psychological and interpersonal mechanisms by collecting new data from participants enrolled in the ongoing parent study.

**Budget:** NIA intends to commit \$2,250,000 in both FY 2022 and FY 2023 to fund 4-6 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

### 2. Mechanism-Focused Research to Promote Adherence to Healthful Behaviors to Prevent Mild Cognitive Impairment (MCI) and Alzheimer's Disease and Related Dementias (AD/ADRD) (R61/R33 Clinical Trial Required)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-AG-22-016](#)

**Type:** R61/R33

**Application Due Date:** September 15, 2021 Apply by 5:00 PM local time of applicant organization

**Funding Opportunity Announcement:** This Funding Opportunity Announcement invites R61/R33 applications to address psychological and interpersonal mechanisms driving adherence to behaviors or lifestyle changes relevant to prevention of cognitive decline, Mild Cognitive Impairment (MCI), and Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). Mechanisms of adherence may be studied in new, early- to late-stage (including Stage I-IV) behavior change trials. Successful applications will seek to identify malleable, mechanistic, psychological, or interpersonal targets that, if modified, will strengthen adherence to, maintenance of, and continued/renewed engagement in behaviors that may promote cognitive health and prevent AD/ADRD. This FOA will support pilot research (R61) to identify, measure, and assess the malleability of psychological or interpersonal adherence-relevant targets that, if successful, can transition to an R33 phase for implementation of rigorous, proof-of-concept intervention studies. The transition from the R61 to the R33 phase of the award will be administratively reviewed for and be dependent upon successful completion of the go/no-go criteria specified for the R61 phase.

**Budget:** NIA intends to commit \$3 million in FY 2022 to fund 6-8 awards. For the R61 planning phase, the budget for direct costs may not exceed \$225,000. For the R33 implementation phase, the budget for direct costs may not exceed \$500,000 in any single year. Application budgets need to reflect the actual needs of the proposed project. The maximum period of the combined R61/R33 phases is 5 years, with 1-2 years for the R61 phase and 3-4 years for the R33 phase. Funding of the R33 award will be determined by successful completion of the R61 scientific goals, as determined by NIH.

### 3. Understanding HIV Reservoir Dynamics (P01 Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-AI-21-013](#)

**Type:** P01

**Application Due Date:** July 30, 2021 Apply by 5:00 PM local time of applicant organization

**Funding Opportunity Announcement:** The purpose of this Funding Opportunity Announcement (FOA) is to support multi-disciplinary, Program Project applications aimed at understanding changes in the HIV reservoir over time in different cell types and tissues. A better understanding of the mechanisms that govern HIV reservoir dynamics over time is essential to inform the development of strategies to cure HIV or control viral infection to overcome the need for life-long antiretroviral therapy.

**Budget:** The following NIH components intend to commit the following amounts in FY 2022: NIAID, \$7M and NIMH, \$0.5M to fund a total of 3-4 awards Application budgets are limited to \$1 million per year in direct costs and need to reflect the actual needs of the proposed project. **The scope of the proposed project determines the project period. The maximum project period is 5 years.**

### 4. Development of New Technologies and Bioengineering Solutions for the Advancement of Cell Replacement Therapies for Type 1 Diabetes (T1D) (R01 Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-DK-21-006](#)

**Type:** R01

**Application Due Date:** October 20, 2021 Apply by 5:00 PM local time of applicant organization

**Funding Opportunity Announcement:** This Funding Opportunity Announcement (FOA) encourages applications from institutions/organizations proposing original research addressing barriers that limit progress toward effective cell therapies for type 1 diabetes (T1D). The purpose is to support research leading to the development and testing of novel and supportive technologies for the improvement of cell interventions using novel cell sources, immune-modulatory strategies, biomaterials and devices for T1D treatment.

**Budget:** The NIDDK intends to commit \$3,000,000 in FY 2022 to fund 4-7 awards. The number of awards is contingent upon availability of funds and the submission of a sufficient number of meritorious applications. Application budget is limited \$ 500,000 direct costs per year. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

### 5. Collaboration in Regulatory Systems Strengthening and Standardization Activities to Increase Global Access to Safe and Effective Biological Products (U01) Clinical Trials Not Allowed

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-FD-21-031](#)

**Type:** U01

**Application Due Date:** July 13, 2021, by 11:59 PM Eastern Time.

**Funding Opportunity Announcement:** The Food and Drug Administration (FDA) announces its intention to accept and consider a single source application for award of a Cooperative Agreement to the World Health Organization (WHO) in support of collaboration in regulatory systems strengthening, development of norms and standards, and innovative research to advance global access to safe and effective biological products that meet international standards.

**Budget:** Award(s) will provide one (1) year of support and include future recommended support for four (4) additional year(s) contingent upon annual appropriations, availability of funding and satisfactory awardee performance. FDA/CBER intends to commit up to \$2,000,000 in FY 2021 in support of this grant program. Application budgets need to reflect the actual needs of the proposed project and should not exceed the following in total costs (direct and indirect): \$2,000,000 per year. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

### 6. BRAIN Initiative: Targeted BRAIN Circuits Projects- TargetedBCP (R01 Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-NS-21-013](#)

**Type:** R01

**Application Due Date:** July 07, 2021 and November 10, 2021 Apply by 5:00 PM local time of applicant organization

**Funding Opportunity Announcement:** This FOA solicits applications for research projects that seek to understand how circuit activity gives rise to mental experience and behavior using innovative, methodologically-integrated approaches. The goal is to support adventurous projects that can realize a potentially transformative outcome within 5 years. Applications are expected to address circuit function in the context of specific behaviors or neural systems, such as sensation, perception, attention, reasoning, intention, decision-making, emotion, navigation, communication, or homeostasis. Projects should link theory, data analysis, and/or computational approaches to experimental design and should produce predictive models (conceptual or quantitative). Projects should aim to improve the understanding of circuits of the central nervous system by systematically controlling stimuli and/or behavior while actively recording and/or manipulating dynamic patterns of neural activity. Diverse species or experimental systems and a cross-species/comparative approach are welcome and should be chosen based on their power to address the specific question at hand and to reveal generalizable and fundamental neuroscience principles.

**Budget:** Issuing IC and partner components intend to commit an estimated total of \$15 M to fund 20 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

### 7. BRAIN Initiative: Targeted BRAIN Circuits Planning Projects – TargetedBCPP (R34 Clinical Trials Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-NS-21-014](#)

**Type:** R34

**Application Due Date:** July 07, 2021 and November 10, 2021 Apply by 5:00 PM local time of applicant organization

**Funding Opportunity Announcement:** This R34 FOA solicits applications that offer a limited scope of aims and an approach that will establish feasibility, validity, or other technically qualifying results that, if successful, would support, enable, and/or lay the groundwork for a potential, subsequent Targeted BRAIN Circuits Projects - TargetedBCP R01, as described in the companion FOA (RFA-NS-21-013). Applications should be adventurous exploratory research projects that use innovative, methodologically-integrated approaches to understand how circuit activity gives rise to mental experience and behavior.

**Budget:** BRAIN Initiative intends to commit \$2.5M per year to fund 10 awards. The combined budget for direct costs for the two-year project period may not exceed \$450,000. No more than \$225,000 may be requested in any single year. The scope of the proposed project should determine the project period. The maximum project period is 2 years.

## 8. Cutting Edge Informatics Tools for Illuminating the Druggable Genome (U01 Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-RM-21-020](#)

**Type:** U01

**Application Due Date:** July 15, 2021 Apply by 5:00 PM local time of applicant organization

**Funding Opportunity Announcement:** The overarching goal of this funding opportunity announcement (FOA) for the Common Fund program "Illuminating the Druggable Genome" (IDG; <https://commonfund.nih.gov/idg/>) is to solicit applications to build a set of Cutting Edge Informatics Tools (CEITs) that will augment the capability of the IDG consortium's Knowledge Management Center (KMC) as well as the broader IDG Consortium. Awards will support the IDG Consortium by: (1) developing and deploying tools to enhance the community's ability to process, analyze, and visualize IDG data, (2) prioritizing new data resources and methods to be incorporated into Pharos (<https://pharos.nih.gov/idg/index>) that will strengthen predictions about physiological and disease associations around IDG-eligible understudied proteins (non-olfactory GPCRs, protein kinases, and ion channels), and (3) developing methods to prioritize IDG-eligible understudied proteins for deeper study using experimental assays both developed within the IDG pipeline or by the larger community. The IDG consortium's purpose is to facilitate the unveiling of the functions of selected understudied proteins in the Druggable Genome using experimental and informatics approaches. Currently, this research consortium is composed of multiple Data and Resource Generation Centers (DRGCs), a Knowledge Management Center (KMC), and a Resource Dissemination and Outreach Center (RDOC).

**Budget:** The NIH Common Fund intends to commit \$1,400,000, per year for FY 2022 and FY 2023 contingent upon receiving scientifically meritorious applications. Three awards are anticipated from this solicitation. Application budgets are limited to \$300,000 in total direct costs (excluding subcontract F&A) per year and need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 2 years.

Research Development and Support Division (RDSD),  
Faculty of Medicine and Health Sciences, Stellenbosch University  
5<sup>th</sup> Floor, Teaching Block, Tygerberg Campus.  
Enquiries: *Christa*  
e: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) | t: +27 21 938 9838

Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)  
Stellenbosch University  
2038 Wilcocks Building, Ryneveld Street  
Enquiries: *Lizél*  
e: [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za) | t: +27 21 808 2105